0000899243-21-022068.txt : 20210604 0000899243-21-022068.hdr.sgml : 20210604 20210604170048 ACCESSION NUMBER: 0000899243-21-022068 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210602 FILED AS OF DATE: 20210604 DATE AS OF CHANGE: 20210604 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Templeman Thomas CENTRAL INDEX KEY: 0001654274 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40445 FILM NUMBER: 21997204 MAIL ADDRESS: STREET 1: C/O MEDIVATION, INC. STREET 2: 525 MARKET ST., 36TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Centessa Pharmaceuticals plc CENTRAL INDEX KEY: 0001847903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: THE DOROTHY HODGKIN BUILDING STREET 2: BABRAHAM RESEARCH CAMPUS CITY: BABRAHAM, CAMBRIDGE STATE: X0 ZIP: CB22 3FH BUSINESS PHONE: 44 (0)7767 003904 MAIL ADDRESS: STREET 1: THE DOROTHY HODGKIN BUILDING STREET 2: BABRAHAM RESEARCH CAMPUS CITY: BABRAHAM, CAMBRIDGE STATE: X0 ZIP: CB22 3FH FORMER COMPANY: FORMER CONFORMED NAME: Centessa Pharmaceuticals Ltd DATE OF NAME CHANGE: 20210224 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-02 0 0001847903 Centessa Pharmaceuticals plc CNTA 0001654274 Templeman Thomas C/O CENTESSA PHARMACEUTICALS PLC 3RD FL., 1 ASHLEY RD, ALTRINCHAM CHESHIRE X0 WA14 2DT UNITED KINGDOM 0 1 0 0 Chief Technology Officer Ordinary Shares 2021-06-02 4 P 0 250 20.00 A 250 D Share Option (right to buy) 9.42 2021-04-20 4 A 0 500338 0.00 A 2031-04-20 Ordinary Shares 500338 500338 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital ("Share Split"). This amount has been adjusted to give effect to the Share Split. This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3 25% of the shares subject to such option shall vest and become exercisable on May 17, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter. Represented A Ordinary Shares that were redesignated as Ordinary Shares immediately prior to the closing of the initial public offering. /s/ Marella Thorell, attorney-in-fact 2021-06-04